Herceptin Adjuvant Approval Has 65% Higher Price Than Metastatic Therapy

The average cost per one-year course of Herceptin (trastuzumab) for adjuvant HER2-positive breast cancer will be $38,007, or 65% more than a course for the biologic's metastatic breast cancer indication